CSIMarket Company Name, Ticker, Customers, else..
 
Jasper Therapeutics Inc   (NASDAQ: JSPR)
 
Price: $0.6473 $-0.01 -1.924%
Day's High: $0.6682000160217285 Week Perf: -8.7 %
Day's Low: $ 0.60 30 Day Perf: -24.99 %
Volume (M): 382,639 52 Wk High: $ 2.69
Volume (M$): $ 0 52 Wk Avg: $1.29
Open: $0.66 52 Wk Low: $0.31



 Market Capitalization (Millions $) 19
 Shares Outstanding (Millions) 29
 Employees 22
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Business Description


Jasper Therapeutics Inc is a biotechnology company specializing in the development of cell-based therapies for various diseases. They focus on the use of hematopoietic stem cells (HSCs) to treat cancer, autoimmune disorders, and other genetic diseases. Their innovative approach involves the use of engineered HSCs to improve patient outcomes and reduce the need for traditional transplantation methods. The company aims to revolutionize the field of stem cell therapy by providing safer, more effective treatment options for patients in need.


   Company Address: 2200 Bridge Pkwy Redwood City 94065 CA
   Company Phone Number: 549-1400   Stock Exchange / Ticker: NASDAQ JSPR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -13.21%    
EXEL   -4.59%    
GILD   -3.88%    
IMCR   -9.45%    
IOVA        5.52% 
KRYS   -4.55%    
• View Complete Report
   



Announcement

Class Action Lawsuit Filed Against Jasper Therapeutics Amidst Allegations of Securities Violations

Published Wed, Sep 24 2025 3:26 PM UTC

In a significant development for investors in the biotech sector, Pomerantz LLP, a well-regarded law firm known for its dedication to defending shareholder rights, has announced the filing of a class action lawsuit against Jasper Therapeutics, Inc. (NASDAQ: JSPR) and certain officers of the company. The case, formally registered in the United States District Court for the No...
Announcement

Legal Looms and Revenues Stall Jasper Therapeutics Faces Investor Scrutiny Amid Class Action Challenges,

Published Mon, Sep 22 2025 4:28 AM UTC

Investor Alert: A Close Examination of Jasper Therapeutics Amid Securities Class Action Announcement and Competitive Revenue Decline In a significant development for investors of Jasper Therapeutics, Inc. (NASDAQ: JSPR), the Rosen Law Firm, known for its advocacy of investor rights, has announced the filing of a class action lawsuit. This legal pursuit is specifically geared...
Announcement

Jasper Therapeutics Inc. Under Investigation Amid Fluctuating Stock Performance Investor Advisory Issued by Pomerantz...

Published Thu, Jul 10 2025 2:08 PM UTC

In recent developments, Pomerantz LLP has initiated an investigation into claims on behalf of the investors of Jasper Therapeutics, Inc. (NASDAQ: JSPR), highlighting concerns pertinent to the company’s financial disclosures and trading practices. This announcement, made public on July 10, 2025, has drawn attention to the firm s stock performance amidst a tumultuous trading...
Clinical Study

Jasper Therapeutics Briquilimab Shines Bright with Promising Results in Chronic Inducible Urticaria Study...

Published Mon, Oct 14 2024 11:00 AM UTC

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria: A New Hope for Patients Jasper Therapeutics, a pioneering biopharmaceutical company focused on providing transformative therapies for patients, proudly announced encouraging results from its SPOTLIGHT study involving Briquilimab for the treatment of Chronic Inducible...
Clinical Study

Pioneering Hope in Allergy Treatment Jasper Therapeutics Briquilimab Targets Mast Cell Diseases in Groundbreaking Cl...

Published Tue, Sep 10 2024 11:31 AM UTC

In recent years, the landscape of biotechnology has been enriched by innovative therapeutic approaches aimed at addressing unmet medical needs, particularly in the realm of allergic diseases. Jasper Therapeutics, Inc. (Nasdaq: JSPR), a burgeoning clinical-stage biotechnology company, is at the forefront of this endeavor with its novel antibody therapy, briquilimab. This arti...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 13.15
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.93
Working Capital Ratio 0.93
Leverage Ratio (MRQ) 7.35
Total Debt to Equity 0.28
Interest Coverage (TTM) 18.42
Debt Coverage (TTM) 119.75

Per Share Current
Earnings (TTM) -1.74 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.25 $
Book Value 0.05 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,444,136
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.